Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin

Pharmazie

Volumn 63, Issue 8, 2008, Pages 593-597

  Tian, Jie ^a   Pang, Xiujuan ^a   Yu, Kefu ^a   Liu, Linjie ^a   Zhou, Jun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATION EXCHANGE RESIN; CISPLATIN; NANOPARTICLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; EMULSION; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; MALE; NONHUMAN; PARTICLE SIZE; RAT; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG COMPOUNDING; ELECTROCHEMISTRY; INJECTIONS, INTRAVENOUS; ION EXCHANGE RESINS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 50149095764     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8017     Document Type: Article

References (20)

1. Augey V, Cociglio M, Galtier M, Yearoo R, Pinsani V, Bressolle F (1995) High-performance liquid chromatographic determination of cis- dichlorodiammineplatinum (II) in plasma ultrafiltrate. J Pharm Biomed Anal 13: 1173-1178.
2. Flores AL, Jurado R, Lopez PG (2005) A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples. J Pharmacol Toxicol Meth 52: 366-372.
3. Fujiyama J, Nakase Y, Osaki K (2003) Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release 89: 397-408.
4. Giaccone C (2000) Clinical perspectives on platinum resistance. Drugs 59: 9-17.
5. Giri J, Thakurta SG, Bellare J (2005) Preparation and characterization of phospholipid stablilized uniform sized magnetite nanoparticles. J Magn Magn Mater 293: 62-68.
6. Li TS, Kaneda Y, Saeki K, Ueda K, Zempo N, Esato K (1999) Pharmacokinetic differences between rat tumour and lung tissues following isolated lung perfusion with cisplatin. Eur J Cancer 35: 1846-1850.
7. Liu WP, Zhang YI, Sun JI (2005) Future development of platinum anticancer drugs. Precious Metals 26: 47-52.
8. Macka M, Borak J, Semenkova L (1994) Decomposition of cisplatin in aqueous solutions containing chlorides by ultrasonic energy and light. J Pharm Sci 83: 815-819.
9. Mehnert W, Mader K (2001) Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-169.
10. Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 45: 165-196.
11. Müller RH, Maaßen S, Weyhers H (1996) Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 138: 85-94.
12. Müller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50: 161-170.
13. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, Suzuki T, Yoshino H, Ike O (2002) Organ distribution of cisplatin after intraperitoneal administration of cisplatin -loaded microspheres. Eur J Pharm Biopharm, 54: 1-7.
14. Tang X, He ZG, Yu YL (2000) A study on the stability of the cisplatin aqueous solution. J Shenyang Pharm Univ 17: 405-407.
15. Velinova MJ, Staffhorst RWHM, Mulder WJM (2004) Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim Biophys Acta 1663: 135-142.
16. Wang SN, Deng YH, Bi DZ, Li HQ, Qi LP, Jia N (2002) Determination of the efficiency of ciprofloxacin liposomes by cation exchange resin-first order derivative spectrophotometry. J Shenyang Pharm Univ 19: 192-195.
17. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-1272.
18. Xiao CJ, Qi X R, Aini W (2003) Preparation of cisplatin multivesicular liposomes and release of cisplatin from the liposomes in vitro. Acta Pharm Sin 38: 133-137.
19. Xu PS, Van Kirk EA, Li SY, Murdoch WJ, Ren J, Hussain MD, Radosz M, Shen YQ (2006) Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. Colloids Surf B 48: 50-57.
20. Yotsuyanagi T, Usami M, Noda Y (2002) Computational consideration of cisplatin hydrolysis and acid dissociation in aqueous media: effect of total drug concentration. Int J Pharm 246: 95-104.